XML 62 R52.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Commitments and Contingencies - CFTR Activators and Inhibitors - Additional Information (Details) - CFTR Activators and Inhibitors - USD ($) $ in Millions | 3 Months Ended | 85 Months Ended
--- | --- | ---
Mar. 31, 2024 | Mar. 31, 2024
Commitments and Contingencies [Line Items] |  |
Future percentage of royalty payments based net sales | single-digit |
Development and milestone obligations paid to third party |  | $ 1.6
Developmental Milestone |  |
Commitments and Contingencies [Line Items] |  |
Possible future milestone payments | $ 11.9 |
Future Regulatory Approval and Sales Milestones |  |
Commitments and Contingencies [Line Items] |  |
Possible future milestone payments | 33.0 |
Development and Milestone Payment, Conclusion of Clinical Studies |  |
Commitments and Contingencies [Line Items] |  |
Possible future milestone payments | 1.1 |
Development and Milestone Payment, Conclusion of Clinical Studies | Maximum |  |
Commitments and Contingencies [Line Items] |  |
Possible future milestone payments | $ 3.2 |

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | vnda_CommitmentsAndContingenciesLineItems
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development And Milestone Obligations Paid To Third Party + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future Percentage Of Royalty Payments Based On Net Sales. + References No definition available. + Details
Name: | vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfClinicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |